Eleanor Laise is a reporter for MarketWatch, with her work also appearing in Yahoo Finance and BuradaBiliyorum. She covers a wide range of topics, including pharmaceutical companies, healthcare, biotechnology, and stock market analysis. Eleanor provides insightful reporting and analysis on the latest developments in these industries.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Eleanor's coverage heavily focuses on the healthcare and pharmaceutical industries, particularly in relation to investment analysis and FDA approvals. Her articles often cite data or press releases.
Given her focus, Eleanor would likely welcome pitches from experts who can provide insightful commentary on pharmaceutical developments, investment trends within the healthcare sector, or the implications of FDA decisions on specific companies or industry sectors.
If you have expertise in biotechnology advancements, pharmaceutical market trends, stock analysis related to medical treatments or FDA approval processes, your insights may be valuable for Eleanor’s coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Biogen Inc. BIIB, said Wednesday that it will halt the development and commercialization of its Alzheimer's drug Aduhelm, which drew intense scrutiny
Biogen is halting the development and commercialization of the Alzheimer’s drug Aduhelm, which drew intense scrutiny of its U.S. regulatory process due to...
Shares of Stryker, Boston Scientific and other medical technology companies jumped Wednesday as healthy demand for medical procedures brightened investors’...
By: Eleanor Laise
Merck on Thursday reported fourth-quarter earnings and sales that beat analyst expectations, powered by strong growth in cancer and vaccine products.
By: Eleanor Laise
Amgen on Tuesday reported fourth quarter profits and sales that topped analyst expectations even as revenues dropped for one of its top-selling drugs.
By: Eleanor Laise
Lawmakers have emphasized gaps between U.S. list prices and overseas costs for a handful of drugs made by the three drugmakers.
By: Eleanor Laise
Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are...
By: Eleanor Laise
Biogen on Tuesday reported fourth-quarter results that fell short of Wall Street expectations as uptake of its newer drugs failed to offset declining...
RAPT Therapeutics shares dropped more than 60% premarket on Tuesday after the company said regulators have hit pause on two clinical trials of its...
UnitedHealth Group Inc. shares UNH, fell more than 2% Tuesday after The Wall Street Journal reported that the Department of Justice has launched an antitrust investigation into the health insurance giant.
(833) 317-6278 
